Merck Coughs Up a Failure With Its "Pipeline in a Product"
Merck (NYSE: MRK) has high hopes for gefapixant, an experimental drug that it's referred to as a "pipeline in a product." However, the U.S. Food and Drug Administration (FDA) recently poured some cold water on those hopes, turning down approval for the drug in treating chronic cough. In this Motley Fool Live video, recorded on Jan. 26, Fool contributors Keith Speights and Brian Orelli discuss why the FDA gave a thumbs-down to gefapixant.
Source Fool.com
